2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Patient and physician perspectives on the care and assistance needs in Huntington’s disease

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews

C. Ervin, J. Sutphin, A. Thach, A. Lee, C. Mansfield, J. Coulter (Research Triangle Park, NC, USA)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Patient organisation collaboration to advance patient engagement in Parkinson’s research

N. Ratcliffe, K. Schroeder (New York, NY, USA)

Other · Agora 2 West, Level 2

1:45pm-3:15pm: People with Parkinson’s Disease (PPD): disease, stigma and the others

M. Bacigalupe (La Plata, Argentina)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Permanent chorea in 76-years-old female with poorly controlled diabetes

F. Abu Ahmad, A. Socher, A. Gadoth, O. Aizenstein, A. Hilel, R. Hurvitz-Alon, N. Giladi, T. Gurevich (Tel Aviv, Israel)

Choreas (Non-Huntington’s Disease) · Les Muses, Level 3

1:45pm-3:15pm: PEX 16: EXPANDING THE CLINICAL SPECTRUM OF PEROXISOMAL BIOGENESIS DISORDERS

D. N, J. Agadi (Bangalore, India)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3

1:45pm-3:15pm: Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease

G. Loewen, P. Lewitt, C. Olanow, K. Kieburtz, G. Liang, R. Jimenez, K. Olson, E. Roberts (San Diego, CA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

NAO. Kanzato (Okinawa, Japan)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia

J. González-Fernández, E. Zucchet, P. Calap-Quintana, P. González Cabo, MD. Moltó Ruiz (València, Spain)

Ataxia · Les Muses, Level 3